John P. Wilson, Ph.D., & CEO, Guest Spoke at the National University of Singapore Educating Students on Entrepreneurship

Dr. John Wilson

"I am not into Bioscience, but you gave me a new dimension to be an entrepreneur," states a PhD student regarding John Wilson's speech.

LOS ANGELES, CA, UNITED STATES, November 30, 2020 / — Dr. John P. Wilson, PhD and CEO of ProtiFi, LLC, made time yet again to educate in a very recent special event. He was invited to be the special guest speaker of the talk, "Academia, Industry and Entrepreneurship: Which is Your Parachute?", to the National University of Singapore (NUS). NUS is ranked consistently as one of the world's top universities and offers the most extensive college degree courses in Singapore. The invite came from Graduate Students Society National University of Singapore(GSS). Most young professionals, such as PhD candidates and students, of the National University of Singapore were in attendance. The call was 7 am ET, 8 pm Singapore time via Zoom on November 25, 2020.

Dr. Wilson has been passionately advocating for the potential and value of entrepreneurship, especially in biotech, for more than a decade. His latest outing was yet again a unanimous success and praised by young professionals at NSU: "Your webinar organized by NUS was exceptionally amazing. I am not into Bioscience, but you gave me a new dimension to be an entrepreneur. I am currently working on a Rural technology solution for India. I am the guy who said "Perseverance". I will remember the word for years to come," praises Gokul M.C, a PhD student at NSU. The response “perseverance” was in reply to Dr. Wilson’s question “What personality trait is most essential to being successful entrepreneur?”.

Dr. Wilson shared his passion and purpose in the journey to do good through entrepreneurship by vigilantly using the gifts we each receive. His own journey began as a child making things to sell in a workshop with his father to supplement the income of his two social worker parents in the farm country of Oregon and led through multiple difficult working experiences. In grad school he nearly died from simultaneous lung infections and meningitis, an experience that left him with first-hand knowledge of the value of health and experience of COVID19 victims. He then went on to the #1 ranked Cold Spring Harbor Laboratory where he developed seminal technologies to enable precision medicine and personalized health, which he launched as ProtiFi, LLC.

"Thanks to GSS, I got to know you. It was very motivational and thank you for sharing your experiences," states Abigail Tan, PhD candidate at NSU.

Dr. Wilson believes entrepreneurship is essential to effecting real change in the many problems of the world and is, for that reason, passionate about education. ProtiFi, LLC, which Dr. Wilson founded, has as part of its broader mission to be “…an active, integral part of the omics community that, through collaboration, education and contribution, strives to advance humanity's scientific understanding." Dr. Wilson’s continued talks fulfill the mission of education.

"I got to know you through a webinar session and it was very inspiring. Thank you for sharing your experiences," concludes Xiaoyang Chen, PhD candidate at NSU.

Dr. Wilson actually gave a very similar talk to the American Medical Student Association via invitation from the New York Institute of Technology (NYIT) on November 17th. The American Medical Student Association, founded in 1950 and based in Washington, D.C., is the oldest and largest independent association of physicians-in-training in the United States. AMSA is a student-governed, national organization.

"Education of our youngest generation about the power of entrepreneurship to make transformative changes can solve the very big problems we face," concludes Dr. Wilson. “In 2008, I founded a 501(c)3 not for profit called NYC Bio which had the goal of facilitating the growth of a biotech cluster through education, networking and collaboration. Fast forward 12 years and while it worked, and I'm still educating because education (or not) is how we make transformative changes (or not). Giving some direction and advice to our future generations who could, by example, cure cancer or malaria, is well worth the time. Young people need to know by example that they can chase their passions and earn a living in the pursuit of good ends."

Dr. John Wilson

John Wilson, Ph.D., is CEO and Co-Founder of ProtiFi, LLC producing solutions for protein and proteomics analysis. He also founded NYC Bio, a non-profit dedicated to collaboration and innovation in biotech. John is “problem solver” and does just that. Having done proteomics since 2001, he got his PhD from The Rockefeller University and joined Cold Spring Harbor Laboratory (CHSL) as a postdoc with Darryl. Together, they’ve made cool technology. John is passionate about R&D that makes a difference.

Aurora DeRose
Boundless Media Inc.
+ +1 951-870-0099
email us here

Source: EIN Presswire

Emil Malak Pens an Op-ed: New antibody resistant coronavirus mutation N493K; Focus should be on testing

Emil Malak, CEO Voip-Pal, well versed in global politics, culture and health


VOIP-PAL Corporate Logo

CEOCFO Magazine logo

There is an urgent need for continuous testing every three days as well as making COVID-19 testing more widely available through innovative means such as testing vending machines.”

— Emil Malak

WASHINGTON, DC, US, November 30, 2020 / — CEOCFO Magazine, an independent investment publication that highlights important technologies and companies, today announced it has published an op-ed ( by Voip-Pal CEO Emil Malak. Inc., Voip-Pal (OTCQB: VPLM), a Bellevue, Washington based company is an inventor and pioneer of the switching technology now being used by many of the world's largest telecommunication and social networking companies, without which they could not connect Landline phone calls to Internet phone calls. Mr. Malak has other business ventures and is well versed in global politics and culture.

In February of this year (2020), just as the world was waking up to the news that people were fleeing Wuhan China, headed to worldwide destinations with the deadly coronavirus, Mr. Malak wrote his very first Op-ed on the subject. In the title of his article, “A Global Pandemic Has Already Started” Mr. Malak declared the novel coronavirus to be a worldwide pandemic one month before the World Health Organization did. Since then we have seen several of Mr. Malek’s predictions on the virus come true.

In his most recent op-ed, Mr. Malak discussed the new antibody resistant coronavirus mutation N493K. “The neutralizing antibodies that patients develop after being infected with a virus or following vaccination are not proving to be effective against this new mutant. The N439K mutation so-far is proving to be resistant to antibodies.

He continued, “N439K has already been identified in twelve countries and is increasing infection rates in the United States and Europe. As a result, within the next four weeks we could potentially see death rates increase. Authors of a recent study on the new coronavirus mutant conclude their findings could have consequences, not only on the efficacy of emerging vaccines but also the efficacy of antibody therapeutics.”

With studies such as the one by The University of Vermont Medical Center yet to be done, Mr. Malak who is very pro-vaccine and believes they save lives cautioned, “I have the utmost respect for politicians on both sides of the aisle that have dedicated their efforts into eradicating the coronavirus. One of the challenges is there are still too many unknowns before we can roll out a safe vaccine solution. Do neutralizing antibodies indeed vanish within a few months? Will antibody dependent enhancement (ADE) put those vaccinated in danger? Could a vaccinated person, thinking they are immune to COVID-19 become an asymptomatic carrier and spread the virus? How many doses of the vaccine will people need per year? Some suggest three of four doses per year to be safe. What about side effects? Will spike protein mutations complicate matters?”

Malak has repeatedly warned in his op-eds over the past nine months about the need to gather adequate data of at least two years before allowing a vaccine to go to the market. Recalling the mistakes of the 1960’s Thalidomide tragedy that led to tens of thousands of children born with birth defects, Malak wrote, “We need to learn from these tragedies and never repeat the same mistakes. Rushing into any drug or vaccine could lead to catastrophic consequences.”

Pointing to a study by Danish researches, Mr. Malak discusses another concern in the possibility that today’s vaccine may not work tomorrow because of virus mutation, “Researchers have documented at least two mutations of the coronavirus. In one instance the genetic sequence within the spike protein changed the position of the “614 G” aspartic acid (contains an amino acid and a carboxylic acid) to an “amino acid glycine.” That single change within the spike protein created a new COVID-19-2.0, far more contagious and deadly than the original. The second mutation was recently discovered in the mink farms of Denmark; two amino acid mutations within the spike protein. It is valid to question whether a vaccine would be effective after a mutation takes place in the spike protein. We do not know when, nor how frequently a mutation will take place, rendering the vaccine ineffective each time. Another important question that needs to be answered is how effective any COVID-19 vaccine will be on a mutated strain of the virus; a COVID-2.0.”

Mr. Malak continues, “As a result of this new virus all of Denmark’s 17 million farmed minks in their 400 mink farms are being destroyed and 240 or more mink farm workers are currently infected. This latest development provides even more reason why the focus should be on developing more effective therapeutics,” said Mr. Malak.

Mr. calls for what he calls, “The hammer and the dance” – for a new non-political task force. “It is necessary to form a national scientific advisory committee that is free from all political influence. The committee would provide two televised updates per week to advise the public of the facts regarding the coronavirus, its spread and what actions need to be taken by each state.”

Below is Mr. Malak’s proposal:
The Hammer – Europe is headed back to total lockdown, referred to as the “hammer” because of the resurgence of coronavirus cases. The virus is back in Europe vigorously, leading government officials to once again shutdown their economies. This radical action will be devastating to businesses and to the overall mental and physical health of Europeans and will hopefully be limited to a very short period.

The Dance – During the hammer period certain actions must be taken to get people back to work:
1. There is an urgent need for continuous testing every three days as well as making COVID-19 testing more widely available through innovative means such as testing vending machines that provide rapid results in one minute. Those that test negative are free to go to work, restaurants and live their lives normally. Those who test positive will seek medical attention and self-quarantine. More simple, rapid self-testing kits are needed.
2. Reconfigure workplaces providing the means for social distancing, disinfectants and mask wearing indoors.
3. Limit the size of indoor gatherings.
4. Indoor locations like restaurants, bars, and conference centers etc. could be retrofitted with air conditioning systems that burn out the virus during circulation cycles.
5. Close down tattoo parlors, massage parlors and prostitution businesses. Those with addictions should be treated in proper medical facilities.

People that do not adjust to the new norms necessary to deal with the virus will be leaving themselves vulnerable to potential infection and risks associated with the virus which includes death.

Malak, who has many years of experience dealing with the U.S. patent system hinted he may be writing a future article on the current state of patents in the United States saying, “Unfortunately, owning a U.S. patent today can be meaningless. It is no longer an asset but a liability.”

Bud Wayne
CEOCFO Magazine
+1 570-851-1745
email us here

Source: EIN Presswire

Croptimistic and Climate FieldView Launch API: Full Release Now Available

SWAT MAPS viewer in Climate FieldView

NAICAM, SASKATCHEWAN, CANADA, November 30, 2020 / — An Application Programming Interface (“API”) between Croptimistic Technology Inc. (“Croptimistic”) and Climate FieldView™ (“FieldView”) has been developed to facilitate file sharing between the FieldView platform and Croptimistic’s software platform, CropRecords. The full release is now available (see bottom of page for connection instructions).

Croptimistic is an international AgTech company that provides SWAT MAPS, a turn-key variable rate process that prioritizes Soil, Water, and Topography factors of fields for the creation of management zones. The CropRecords software is the development platform for the entire SWAT MAPS brand and all maps are accessible in the app.

The FieldView platform allows farmers to collect, stream, and analyze operational data across farms and equipment. Their digital maps interface allows viewers to collect and visualize data in real-time as well as import and export maps from other platforms, such as what is now available with SWAT MAPS through the CropRecords API.

Maps found in the CropRecords app, including Croptimistic’s patented Soil, Water, and Topography Maps (“SWAT MAPS”) can now be viewed in FieldView as imagery files. With a user’s consent, the API allows Croptimistic to pull as-applied/yield maps from FieldView, which will be accessible in the CropRecords app. This API is extremely valuable to joint users of FieldView and SWAT MAPS.

Jack Seitz, VP of Sales at Croptimistic, says, “This API gives our clients and partners who use FieldView maximal flexibility in viewing SWAT MAPS and sharing data between CropRecords and FieldView. It also provides a tremendous opportunity for FieldView users to acquire the world’s only high-resolution soil foundation map without the friction and hassle of having to operate in multiple platforms independently. We’re excited to launch this API and know it provides great opportunity and convenience to SWAT MAPS, CropRecords, and FieldView users around the globe.”

To learn how to connect CropRecords to FieldView via API, visit Please contact with any questions.

Denise Hockaday | Canada Climate Business Lead
Climate Corporation

Trevor Friesen | SWAT Technology Specialist
Croptimistic Technology Inc.
Visit us on social media:

Source: EIN Presswire

Dr. Paul Elliott, Neurologist, Celebrates 19 Years of Distinguished Service with the Epilepsy Foundation of Florida

Dr. Paul Elliott, Neurologist, Celebrates 19 Years of Distinguished Service with the Epilepsy Foundation of Florida

Dr. Paul Elliott, Neurologist, Celebrates 19 Years of Distinguished Service with the Epilepsy Foundation of Florida

Neurologist, Dr. Paul Elliott is pleased to announce that he has devoted nearly two very productive decades of work at the Epilepsy Foundation of Florida

STUART, FL, UNITED STATES, November 30, 2020 / — Neurologist, Dr. Paul Elliott is pleased to announce that he has devoted nearly two very productive decades of work to aid the collective efforts of the medical and scientific professionals at the Epilepsy Foundation of Florida.

The Epilepsy Foundation of Florida is just one chapter in a national network of charitable organizations that provide services and programs for those who are dealing with epilepsy across the nation. These services include education on the science of epilepsy, its treatment, and ways an epileptic can better cope with this condition.

These services include a 24/7 help line, community forums, a children’s activity program, seizure education, the “My Seizure Diary” free self management tool advocacy, support for sudden unexpected death in epilepsy (SUDEP) support, a wellness institute, and research.
As a board certified Occupational and Neurological Medicine. Dr. Paul Elliott has been a valuable asset to the foundation in the areas of research, education, and advocacy.

Dr. Paul Elliott has worked closely with the experts at the Epilepsy Foundation of Florida to curate a robust research library and network that encompass the spectrum of discovery from concept to development. Dr. Paul Elliott has helped the Foundation to foster the development of new research professionals to support fresh avenues of discovery which will lead to better quality care and treatments.

In the area of advocacy, Dr. Paul Elliott has been invaluable with his in depth knowledge of neurobiology and occupational medicine. Because he has published and presented scientific studies in Neurological Medicine, occupational medicine, and Osteopathy, his advocacy has come with a depth and breadth of knowledge and authority which make his efforts eminently valuable.

Likewise, in the foundation’s educational efforts, Dr. Paul Elliott has been a great resource. While scientific knowledge of the brain is far from complete, Dr. Paul Elliott’s expertise and dedication to the cause have brought valuable insights to many people struggling with epilepsy, the friends and families of those living with epilepsy, those who directly care for someone living with the condition, and for many professionals who provide care and treatment for the condition.

Dr. Paul Elliott’s contributions in time and donations to the foundation have also been instrumental in the progress of the foundation’s Wellness Institute. This organization is dedicated to the prospect that those who live with epilepsy are entitled to the fullest and most productive life possible.

Today, Dr. Paul Elliott continues to provide Adult Neurological Consultation and Diagnostic Testing for patients dealing with a host of conditions and has been praised highly by both his peers and patients.

Caroline Hunter
Web Presence, LLC
email us here
Visit us on social media:

Source: EIN Presswire

Biologics Industry To Recover From COVID-19 Crisis At 15% CAGR

Biologics Market Report 2020-30: COVID-19 Impact And Recovery

Biologics Global Market Report 2020-30: COVID-19 Impact And Recovery

The Business Research Company’s Biologics Market Report – Opportunities And Strategies – Global Forecast To 2030

LONDON, GREATER LONDON, UK, November 30, 2020 / — Avail up to 50% off on ALL research reports at: Offer applies until Dec 31st.

Biologics are being widely used to provide effective treatment for many complex diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease that have limited treatment options. According to a biologics market overview by TBRC, there has been a significant advance in the treatment of rheumatoid arthritis patients who do not respond to traditional disease-modifying anti-rheumatic drugs. The key biologics used for the treatment of rheumatoid arthritis include Abatacept (Orencia), Adalimumab (Humira), Anakinra (Kineret), Infliximab (Remicade), and Rituximab (Rituxan). Key biologics used to treat psoriasis include Adalimumab (Humira), Etanercept (Enbrel), Infliximab (Remicade), Secukinumab (Cosentyx). Cimzia (certolizumab pegol), Humira (adalimumab), and Remicade (infliximab), Tysabri (natalizumab) are biologics that are used to treat Crohn’s disease.

The biologics market report covers sales of biologics and related services by entities that produce biologics to treat and prevent various microbial diseases and cancers. This industry includes establishments that produce products that are composed of sugars, proteins, nucleic acids, and a combination of all these substances isolated from humans, animal and microorganisms or produced from biotechnology methods.

Due to the worldwide supply and demand failures of drugs due to the COVID-19 outbreak, the global biologics market size is expected to decline from $269.2 billion in 2019 to $239.2 billion in 2020 at a compound annual growth rate (CAGR) of -11.2%. Biologic drug shortages because of an inadequate production of biologics is hampering the market growth. This inadequate or slowed production is due to the restrictions imposed by governments of various countries to shutdown factories or function with minimal staffing to contain the spread of virus and keep the staff safe. The market is then expected to recover and grow at a CAGR of 15% from 2021 and reach $464.7 billion in 2023.

Here Is A List Of Similar Reports By The Business Research Company:

Oral Biologics And Biosimilars Market – By Therapeutic Mechanism (Tumor Necrosis Factor-Alpha Inhibitors, Lymphocyte Modulators, Interleukin Inhibitors, GPCR (insulin, growth hormone, parathyroid hormone) Modulators, Immunostimulants, Others), By Disease (Diabetes, Arthritis & Chron`s Disease, Cancer, Infectious Diseases, Other Autoimmune Diseases, Others Diseases), By Molecule Type (Vaccines, Proteins & Peptides, Monoclonal Antibodies, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region, Opportunities And Strategies – Global Forecast To 2030

Pharmaceuticals Market – By Type (Pharmaceutical Drugs, Biologics), By Type Of Pharmaceutical Drugs (Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Musculoskeletal Disorder Drugs, Central Nervous System Drugs, Oncology Drugs, Ophthalmology Drugs, Respiratory Diseases Drugs), By Type Of Biologics Drugs (Monoclonal Antibodies (MAbS), Therapeutic Proteins, Vaccines), And By Region, Opportunities And Strategies – Global Forecast To 2030

Pharmaceutical Drugs And Biologics Logistics Market – By Type (Cold-Chain Logistics And Non-Cold Chain Logistics), And By Region, Opportunities And Strategies – Global Forecast To 2021

Interested to know more about The Business Research Company?
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
email us here
Visit us on social media:

Source: EIN Presswire

R3 Stem Cell International Now Offering Stem Cell and Exosome Therapy Promotion for Canada

Stem Cell Therapy in Canada

best stem cell company

Best Stem Cell Clinic Canada

The US and International leader in regenerative therapies, R3 Stem Cell, is now offering Canada a promotional special for stem cell and exosome therapies.

Patients from Canada receive quality stem cell biologics with high cell counts for extremely affordable pricing at R3 International, and now 50 billion exosomes for free!”

— David Greene, MD, MBA

SCOTTSDALE, ARIZONA, USA, November 30, 2020 / — The US and International leader in regenerative therapies, R3 Stem Cell, is now offering Canada a promotional special for stem cell and exosome therapies. This includes a free 50 billion exosome therapy for each procedure over 50 million stem cells.

The procedures have shown to be extremely helpful for many medical conditions, including orthopedic, autoimmune, neurologic, autism, organ failure and for anti aging as well. R3 International has special stem cell programs for those with autism, kidney failure, COPD, post-stroke, diabetes and more.

R3 Stem Cell’s Centers have performed over 15,000 procedures in the past eight years. In that time, no patients have experienced a significant adverse event, with patient satisfaction exceeding 85%.

Patients have been treated from all Canadian cities, big and small. This includes Montreal, Toronto, Vancouver, Ottawa, Quebec, Hamilton, and surrounding areas. The stem cell therapy for Canada includes anywhere between 30 million and 200 million stem cells, with the treatments being administered by highly skilled doctors either by injection, intravenous, intrathecal, intramuscular or lymphatic.

The cost of stem cell therapy in Canada starts at only $2950 for 30 million cells, with an extra $1000 for 50 million cells. Exosomes are stem cell byproducts that have shown to be exceptionally beneficial when used in conjunction with stem cell therapies. The stem cell treatments and exosome therapies are performed at multiple Centers in Mexico, including Cancun, Tijuana and Mexicali.

All ground transportation is included, with VIP escorts from the airport and hotel to the clinic for the procedures. Each patients has a Personal Concierge Representative to assist with travel logistics and any questions during the process. Each patient undergoes a free virtual consultation with one of R3’s expert stem cell doctors.

According to R3 CEO David Greene, MD, MBA, “We worked very hard to ensure patients receive quality stem cell biologics with high cell counts for extremely affordable pricing. Our Centers are part of hospitals, surgery centers or medical complexes in order to make sure the most contemporary resources are available.”

Currently, almost half of R3’s patient base internationally comes from referrals and repeat patients. "That really says a lot about how successful the stem cell procedures are for patients. The kids with autism, the patients with kidney or lung issues and those with diabetes are often so happy they send in their friends!" added Dr. Greene.

For those in Canada interested in stem cell therapy, call R3 today to set up a free phone consultation at +1 (888) 988-0515 or visit the website at for more information.

David Greene, MD, MBA
R3 Stem Cell International
+1 888-988-0515
email us here

Source: EIN Presswire

Discover EBRAINS: A look inside Europe’s new platform for the brain

BRUSSELS, BELGIUM, November 30, 2020 / — The publication Discover EBRAINS introduces the powerful EBRAINS research infrastructure to the world. EBRAINS has been created by the EU-funded Human Brain Project, and offers an extensive portfolio of brain data, scientific services, digital tools and computing resources for researchers and industry. The paper discusses the transformative impact of EBRAINS for neuroscience, brain medicine, and brain-inspired innovation in Europe.

EBRAINS is an accelerator for European ambitions in multidisciplinary brain research, combining cutting-edge neuroscience, high-performance computing and artificial intelligence. It offers researchers an extensive range of brain data and a digital research environment that connects many of the most advanced European lab facilities, supercomputing centers, clinics and technology hubs in a unique integrated system.

“We are on the cusp of a new era in brain research – unprecedented technologies are put at the service of science, while innovators are taking more and more ideas from neuroscience”, says Pawel Swieboda, CEO of EBRAINS and Director General of the Human Brain Project. "Now we show prospective users what this new infrastructure is all about, the many ways to engage with us on further co-developing it, and how it can help them make their mark in these rapidly growing fields.”

Synergy between neuroscience and technology

Today, high speed computing is changing the game in tackling brain complexity, neurotechnologies are becoming one of the global megatrends in health, and AI-developers are again looking at the brain for inspiration.

“Europe took an early lead in these areas with the Human Brain Project, which sits exactly at the intersection of brain science and computing”, says Katrin Amunts, Scientific Research Director of the HBP. Over the last seven years, the HBP teams, spread across Europe, have built, tested and used the digitally connected research platforms of EBRAINS in a Co-Design approach.

As part of its transitioning into a sustainable infrastructure, EBRAINS has applied for inclusion into the European ESFRI Roadmap, seeking to become a permanent addition to the EU’s research landscape, thereby contributing to accelerate neuroscience applications in industry and medicine.

A look inside (
EBRAINS’ ambition is to provide the scientific community with an open state-of-the-art cloud-based ecosystem that fosters collaborative brain science and paves the way to ground-breaking discovery.

It offers unique resources like the most comprehensive 3D-atlas of the human brain, a Medical Informatics Platform for hospitals, simulation engines like The Virtual Brain, a neurorobotics platform, and access to supercompers of the European FENIX-network, as well as neuromorphic computers, which are modelled after the brain. A range of tailor-made tools helps scientists find, analyse, distribute, visualize and integrate brain data for their research. All components are available through a single online access point at, and can be linked according to the concrete needs of a project.

Coming up: The HBP Science Case
In January, the publication of the Human Brain Project’s “Science Case”, will follow, describing the interplay of different scientific disciplines with the novel Research Infrastructure, the Human Brain Project’s vision of merging neuroscience, computing & technology in Europe, and the current research foci of the project for its final phase until 2023.

Digital event series
The two back-to-back publications are connected to several digital events, which present both the elements of the infrastructure itself and the current breakthrough research paradigms it enables in the HBP.

Politico Event
Tuesday, December 1, 2020 – 5 – 6 PM CET
European research and innovation beyond 2020
Presented by EBRAINS
This POLITICO event will bring together policymakers of the European Commission, scientific experts and industry leaders for a Panel discussion on the future of European research and innovation. EBRAINS CEO and HBP Director General Pawel Swieboda will deliver the opening remarks.

Brain Matters Webinar
Since October, a new webinar series presents the HBP’s research focus areas on a monthly basis.

The third edition on December 10 will focus on Neurotechnology with researchers Rainer Goebel, Steve Furber and Christopher Summerfield.

Watch recordings of the first two editons here:

EBRAINS – In Search of Breakthroughs in Science and Medicine
with Katrin Amunts, Simon Eickhoff and Viktor Jirsa

Networks for Consciousness & Medical Use Cases
with Mavi Sanchez-Vives, Marcello Massimini and Pieter Roelfsema

HBP Science Case Webinar
To be announced

Peter Zekert
Human Brain Project
+49 2461 6196860
email us here

Source: EIN Presswire

ITU Translation Service Introduces A Wide Range of Translation Service Up to 150 Languages







Our ability to deliver outstanding results for our clients starts with our team of smart and capable translators and interpreters.”


MIAMI, FLORIDA, UNITED STATES, November 30, 2020 / — ITU Translation Service is a one-stop translation provider. The company is a certified translation service and has many years of experience in providing language service.

ITU Translation Service is a certified language service provider for businesses and individuals, introduces translation and interpretation services with over 150 languages. The company is a professional language service provider with the qualifications of the ATA. (American Translators Association) and the team are professional linguists with good industry experience. The company representative explained that their company offers a wide range of language services that include Certified Translations and Legal Transcription Services, including translation services of medical, financial, scientific, academic & education materials, and many more. The company also offers Voice-Over, subtitling, dubbing for animation videos in multiple languages. They can translate into 150 languages, and specifically in English, Spanish, Portuguese, French, German, Italian, Arabic, Russian, Chinese, and Haitian Creole.

ITU Translation Service Miami is the best document translation services and has been working with worldwide clients since 2017. Besides professional translation services for academic, science, and medical, the company also provides Affidavits, Apostille, and Online Notarization. In addition to the service, ITU Translation Service is also available to translate for website localization purposes, multi-languages for desktop publishing, Remote Simultaneous Interpretation (RSI), and many more. Its translation service for website localization allows individuals or businesses to get diverse languages of their service. Hence, they will get clear communication and sales strategies.

The certified translation service of ITU Translation Service is the best choice for businesses and individuals who want to get their translation result written professionally and quick turnaround. They also offer their services at competitive prices and guarantee their customers' satisfaction.

Cesar Arana has used ITU Translation Service Fort Lauderdale and is satisfied with the result he received. He said, "Thank you for the translation service. The result was very professional and organized work. ITU Translation Service customer service was patient and spectacular." Other than that, ITU Translation Service provides free language consultation and free quote online 24/7.

ITU Translation Service
ITU Translation Service is a top-notch language translation service based in Miami, FL. The company has been established since 2017. Their services include document translation, voice-over, interpreter service, captioning, subtitling, e-learning videos, language solution for businesses and individuals, and many more. For more information about ITU Translation Service language solution, please visit

Carla Soto
ITU Translation Service
+1 305-896-5896
email us here

Source: EIN Presswire

North America Accounts For Almost 44% Of The Bovine Mastitis Drugs And Diagnostics Market

Bovine Mastitis Drugs And Diagnostics Market Report 2020-30: COVID-19 Implications And Growth

Bovine Mastitis Drugs And Diagnostics Global Market Report 2020-30: COVID-19 Implications And Growth

The Business Research Company’s Bovine Mastitis Drugs And Diagnostics Market Report – Opportunities And Strategies – Global Forecast To 2030

LONDON, GREATER LONDON, UK, November 30, 2020 / — Avail up to 50% off on ALL research reports at: Offer applies until Dec 31st.

North America was the largest region in the global bovine mastitis drugs and diagnostics market, accounting for 43.8% of the total in 2019. It was followed by Asia Pacific, Western Europe, and then the other regions. Going forward, the fastest-growing regions in the bovine mastitis drugs and diagnostics market will be North America and Asia Pacific, where growth will be at CAGRs of 6.7% and 5.9% respectively. These will be followed by Africa, and the Middle East, where the markets are expected to grow at CAGRs of 5.1% and 3.9% respectively. The COVID-19 pandemic has decreased short-term potential growth opportunities for the bovine mastitis drugs industry.

The global bovine mastitis drugs market is concentrated, with a small number of large players the market. The top ten competitors in the market made up to 59.4% of the total market in 2019. Major players in the market include Zoetis Inc., Bayer AG, Elanco Animal Health, Merck and Co., and Boehringer Ingelheim GmbH.

The global bovine mastitis drugs and diagnostics market reached a value of nearly $1.51 billion in 2019, having increased at a compound annual growth rate (CAGR) of 4.5% since 2015. The market is expected to decline from $1.51 billion in 2019 to $1.32 billion in 2020 at a rate of -12.3%. The decline is mainly due to lockdown and social distancing norms imposed by various countries and economic slowdown across countries owing to the COVID-19 outbreak and the measures to contain it. The market is then expected to recover and grow at a CAGR of 4.6% from 2021 ad reach $1.86 billion in 2023. The market is expected to reach $2.05 billion by 2025, and $2.71 billion by 2030.

To continue this growth, market-trend-based strategies for the bovine mastitis diagnostics tests market include investing in developing nanoparticles as substitutes of conventional drugs, focusing on the research and development of innovative mastitis diagnostic kits, focusing on the development of innovative biosensors to improve bovine mastitis diagnosis, focusing on the development of non-antibiotic therapy, and integrating machine learning. Player-adopted strategies in the bovine mastitis drugs and diagnostics market include expanding through new drugs, expanding through acquisitions, and expanding through strategic collaborations.

Here Is A List Of Similar Reports By The Business Research Company:
Animal Medicine Market – By Type Of Medicine (Veterinary Pharmaceuticals, Feed Additives), By Type Of Additive (Antibiotics, Amino Acids And Antioxidants, Vitamins, Acidifiers, Enzymes, Others), By Type Of Animal (Cattle (Dairy And Meat Purposes), Poultry, Other Farm Animals, Dogs And Cats, Other Companion Animals), By Drug Type (Branded, Generic), By Type Of Prescription (OTC, Prescription), By Route Of Administration (Oral, Intravenous, Subcutaneous, Others), By Distribution Channel (Vet Services, Online, Others), By Level Of Regulation (Highly Regulated Countries, Loosely Regulated Countries), And By Region, Opportunities And Strategies – Global Forecast To 2030

Veterinary Pharmaceuticals Market – By Animal Type (Livestock, Companion Animal), By Type Of Pharmaceutical (Veterinary Parasiticides, Veterinary Vaccines, Veterinary Antibiotics, Others), By Administration Route (Oral, Others), By End Use, And By Region, Opportunities And Strategies – Global Forecast To 2030

Animal Growth Promoters and Performance Enhancers Global Market Report 2020-30: COVID 19 Growth and Change

Veterinary Imaging Equipment Global Market Report 2020-30: COVID 19 Growth and Change

Companion Animal Veterinary Vaccines Global Market Report 2020-30: COVID 19 Growth and Change

Veterinary Disposables Global Market Report 2020-30: COVID 19 Growth and Change

Interested to know more about The Business Research Company?
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
email us here
Visit us on social media:

Source: EIN Presswire

A New Partnership in the Horizon: UK Aerospace Giant and an Australian Defence Broker & Advanced Manufacturing Company

Glossy golden color globe with three pointe white strippes from the left side of the globe toward the right side but not quiet reaching the right side, with a pointed end.

Glaive International Defence Pty Ltd

Marques Aviation Ltd

Oxford Aerospace Academy

Glaive International Defence Pty. Ltd. and Marques Aviation Ltd. aerospace and defence companies announce an R&D, manufacturing and commercial partnership

SYDNEY, NEW SOUTH WALES, AUSTRALIA, November 30, 2020 / — Glaive International Defence Pty. Ltd. (Sydney, Australia) and Marques Aviation Ltd. (London, UK) aerospace and defence companies are proud to announce an R&D, manufacturing and commercial partnership which will see Glaive International Defence manufacture advanced UAVs in Australia.

This new partnership between Glaive International Defence and Marques Aviation is set to send some ripples among the Aerospace and Defence Industries, as it lays the foundation of new and upcoming innovations in this sector. Glaive International Defence Pty Ltd, a 100% Australian owned company and Defence Technology Broker licensed by the Australian Defence Department has evolved to manufacture high-end commercial and military unmanned aircraft. The new partnership with Marques Aviation represents a great example of Technology Transfer (TT) reinforced by excellent support from the Australian State & Federal Governments to develop manufacturing capability.

Marques Aviation Ltd is a global aerospace company that provides innovative systems, products and solutions in unmanned aircraft systems to governments and commercial clients worldwide. Its team has over 30 years experience in aircraft design and the development of innovative aerospace technologies. The philosophy underlying engineering practice at Marques Aviation Ltd emphasises innovation to develop advanced high-performance unmanned aircraft. The Marques Aviation Group incorporates the Oxford Aerospace Academy which hosts its Oxford Aerospace Research Centre (OARC-UK), a platform that coordinates international R&D consortia for the development of forward-thinking aerospace technologies. OARC-UK will provide R&D programs and education and training via Glaive International Defence’s facilities in Australia.

This new venture will see the creation of Glaive’s new technological Defence Hub in regional Australia, including a new aircraft manufacturing plant and the creation of dozens of local jobs, therefore boosting the local economy. Glaive International Defence’s Founder & CEO, Vincent Marty, said “the collaboration responded to an increasing drive and demand for enterprises to reboot and reposition defence manufacturing in Australia. Acquiring advanced technology in the Defence Industry, manufacturing such high-performance UAVs in Australia, and helping reboot the local economy which has suffered due to Covid-19, falls in line with the Australian Government and the Australian Defence vision of restoring Australian manufacturing and defence sovereignty.”

This technology partnership between Marques Aviation and Glaive International Defence epitomises the beginning of a new exciting era for both companies which will realise the production of innovative ecological unmanned aerial platforms of medium-size characterised by hybrid solar-hydrogen-battery energy systems, AI sensor fusion, AI swarming, smart multi-function materials, intelligent structures and health monitoring, digital cloud based Unmanned Traffic Management (UTM), and Augmented Reality/Virtual Reality (AR/VR) training underpinned by dedicated R&D programs.

Dr Pascual Marques, president of Marques Aviation Ltd – UK, said “We hold ourselves to a high standard in the products we deliver and in the way we conduct ourselves throughout the entire client experience. Our mission is to be at the forefront of technology and innovation, delivering superior capability and maximised cost efficiency” – adding that “the new Glaive’s Technological Defence Hub in regional Australia will serve as a nucleus for the manufacturing of advanced aerospace technologies based on Industry 4.0 large-scale M2M, and Internet-of-Things (IoT) automated and self-monitoring manufacturing principles, high-level business deals facilitation, and training and education in the unmanned aerospace sector”.

Glaive International Defence Pty Ltd
Tel: +61 434499125 / +61 479152168

Marques Aviation Ltd
Tel: +44 (0)7721 784411

Vincent Marty
Glaive International Defence Pty Ltd
+61 434 499 125
email us here
Visit us on social media:

Glaive International Defence & Marques Aviation – partnership presentation

Source: EIN Presswire